Literature DB >> 10551862

A functional linker in human topoisomerase I is required for maximum sensitivity to camptothecin in a DNA relaxation assay.

L Stewart1, G C Ireton, J J Champoux.   

Abstract

Human topoisomerase I is composed of four major domains: the highly charged NH(2)-terminal region, the conserved core domain, the positively charged linker domain, and the highly conserved COOH-terminal domain. Near complete enzyme activity can be reconstituted by combining recombinant polypeptides that approximate the core and COOH-terminal domains, although DNA binding is reduced somewhat for the reconstituted enzyme (Stewart, L., Ireton, G. C., and Champoux, J. J. (1997) J. Mol. Biol. 269, 355-372). A reconstituted enzyme comprising the core domain plus a COOH-terminal fragment containing the complete linker region exhibits the same biochemical properties as a reconstituted enzyme lacking the linker altogether, and thus detachment of the linker from the core domain renders the linker non-functional. The rate of religation by the reconstituted enzyme is increased relative to the forms of the enzyme containing the linker indicating that in the intact enzyme the linker slows religation. Relaxation of plasmid DNA by full-length human topoisomerase I or a 70-kDa form of the enzyme that is missing only the non-essential NH(2)-terminal domain (topo70) is inhibited approximately 16-fold by the anticancer compound, camptothecin, whereas the reconstituted enzyme is nearly resistant to the inhibitory effects of the drug despite similar affinities for the drug by the two forms of the enzyme. Based on these results and in light of the crystal structure of human topoisomerase I, we propose that the linker plays a role in hindering supercoil relaxation during the normal relaxation reaction and that camptothecin inhibition of DNA relaxation depends on a direct effect of the drug on DNA rotation that is also dependent on the linker.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10551862     DOI: 10.1074/jbc.274.46.32950

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

1.  Residues 190-210 of human topoisomerase I are required for enzyme activity in vivo but not in vitro.

Authors:  Morten O Christensen; Hans U Barthelmes; Fritz Boege; Christian Mielke
Journal:  Nucleic Acids Res       Date:  2003-12-15       Impact factor: 16.971

2.  Activation of human topoisomerase I by protein kinase CK2.

Authors:  Barbara Kowalska-Loth; Agnieszka Girstun; Rafal Derlacz; Krzysztof Staroń
Journal:  Mol Biol Rep       Date:  2003-06       Impact factor: 2.316

3.  Role of the linker domain and the 203-214 N-terminal residues in the human topoisomerase I DNA complex dynamics.

Authors:  G Chillemi; M Redinbo; A Bruselles; A Desideri
Journal:  Biophys J       Date:  2004-09-03       Impact factor: 4.033

Review 4.  Human DNA topoisomerase I: relaxation, roles, and damage control.

Authors:  John B Leppard; James J Champoux
Journal:  Chromosoma       Date:  2005-04-14       Impact factor: 4.316

5.  DNA topoisomerase I domain interactions impact enzyme activity and sensitivity to camptothecin.

Authors:  Christine M Wright; Marié van der Merwe; Amanda H DeBrot; Mary-Ann Bjornsti
Journal:  J Biol Chem       Date:  2015-03-20       Impact factor: 5.157

6.  Molecular docking approach on the Topoisomerase I inhibitors series included in the NCI anti-cancer agents mechanism database.

Authors:  Antonino Lauria; Mario Ippolito; Anna Maria Almerico
Journal:  J Mol Model       Date:  2006-10-28       Impact factor: 1.810

7.  8-Oxoguanine rearranges the active site of human topoisomerase I.

Authors:  Diem-Thu Thieu Lesher; Yves Pommier; Lance Stewart; Matthew R Redinbo
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-03       Impact factor: 11.205

8.  Disulfide cross-links reveal conserved features of DNA topoisomerase I architecture and a role for the N terminus in clamp closure.

Authors:  Komaraiah Palle; Luca Pattarello; Marié van der Merwe; Carmen Losasso; Piero Benedetti; Mary-Ann Bjornsti
Journal:  J Biol Chem       Date:  2008-08-08       Impact factor: 5.157

9.  Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin.

Authors:  Marié van der Merwe; Mary-Ann Bjornsti
Journal:  J Biol Chem       Date:  2007-12-04       Impact factor: 5.157

10.  Evidence of the crucial role of the linker domain on the catalytic activity of human topoisomerase I by experimental and simulative characterization of the Lys681Ala mutant.

Authors:  Paola Fiorani; Cinzia Tesauro; Giordano Mancini; Giovanni Chillemi; Ilda D'Annessa; Grazia Graziani; Lucio Tentori; Alessia Muzi; Alessandro Desideri
Journal:  Nucleic Acids Res       Date:  2009-09-18       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.